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Abstract
Background Whilst the dangers of ‘legal highs’ have been widely publicised in the media, very few cases of the neurological 
syndrome associated with the inhalation of nitrous oxide  (N2O) have been reported. Here we set out to raise awareness of 
subacute degeneration of the spinal cord arising from recreational  N2O use so that formal surveillance programs and public 
health interventions can be designed.
Methods Case series documenting the clinical and investigational features of ten consecutive cases of subacute degeneration 
of the spinal cord presenting to a hospital with a tertiary neurosciences service in East London.
Results Sensory disturbance in the lower (± upper) limbs was the commonest presenting feature, along with gait abnormali-
ties and sensory ataxia. MRI imaging of the spine showed the characteristic features of dorsal column hyperintensity on  T2 
weighted sequences. Serum  B12 levels may be normal because subacute degeneration of the spinal cord in this situation is 
triggered by functional rather than absolute  B12 deficiency.
Discussion A high index of suspicion is required to prompt appropriate investigation, make the diagnosis and commence 
treatment early. This is the largest reported series of patients with subacute degeneration of the spinal cord induced by recrea-
tional use of  N2O. However, the number of patients admitted to hospital likely represents the ‘tip of the iceberg’, with many 
less severe presentations remaining undetected. After raising awareness, attention should focus on measuring the extent of 
the problem, the groups affected, and devising ways to prevent potentially long-term neurological damage.
Keywords Subacute degeneration of the spinal cord · Myelopathy · Hydroxocobalamin · Vitamin  B12
Introduction
Nitrous oxide  (N2O or laughing gas) has been used in clini-
cal practice as a dissociative anaesthetic for over 170 years, 
but its recreational use has become widespread, facilitated 
by legal over-the-counter availability.  N2O abuse is rapidly 
rising throughout the USA and UK, and has become the 
seventh most commonly used recreational drug according 
to the Global Drug Survey 2016 [1].
Several case reports have documented the potential for 
 N2O to cause damage to the nervous system through interfer-
ence with vitamin  B12 metabolism, leading to megaloblas-
tic anaemia and subacute degeneration of the spinal cord 
[2–5] which itself can be irreversible [6]. Here, we report 
the largest series of patients with neurological complications 
from  N2O abuse, in an effort to raise awareness and prompt 
appropriate surveillance, so that an adequate public health 
response may be designed and implemented.
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Methods
All adult patients presenting between 1st of November 
2016 and 1st May 2017 to the Emergency Department of 
the Royal London Hospital, with a history of  N2O use 
and symptoms suggestive of subacute degeneration of 
the spinal cord were included. Two patients had a pre-
existing diagnosis of subacute degeneration of the spinal 
cord and re-presented during this period (cases 8 and 10). 
Blood tests were performed to rule out alternative causes 
of myelopathy in most patients, including virology, anti-
nuclear antibodies, anti-neutrophil cytoplasmic antibod-
ies, anti-cardiolipin antibodies, aquaporin 4 antibodies 
and paraneoplastic antibodies. Nutritional deficiencies of 
copper and folate were also routinely tested. Cerebrospi-
nal fluid examination was performed in four patients. All 
patients were seen and examined by an attending consult-
ant neurologist and imaging reported by a consultant neu-
roradiologist. Where serum vitamin  B12 level was normal, 
serum methylmalonic acid (MMA) was also measured. 
Where possible, patients were followed up in the outpa-
tient department. Due to difficulties contacting patients 
(change of address, GP or phone number), not all patients 
were available to provide consent, and therefore all cases 
have been fully anonymised.
Results
Demographics
There were approximately 150,000 attendances to the 
Emergency Department over the 6-month study period. 
Table 1 summarises the clinical features of the ten study 
cases included in this report. The median age of patients 
was 22 years (range 17–26), three were women and seven 
were men. Seven patients were of Bangladeshi descent, 
one Asian, one mixed White-Caribbean and one  was 
White. Eight were current smokers, six drank alcohol 
more than twice per week, and three used other drugs 
recreationally (two used cocaine and one marijuana). On 
average, patients used  N2O around two-three times per 
week, and the number of  N2O canisters consumed ranged 
between 75 and 2000 per week.
Clinical features
Altered sensation in the limbs was the predominant pre-
senting feature (seven had symptoms in the upper limbs 
and all ten had symptoms in the lower limbs). Strength 
was well preserved in most patients. Additional clinical 
features were gait ataxia (n = 8), falls (n = 3), Romberg’s 
sign (n = 6), pseudoathetosis (n = 5), Lhermitte’s phenom-
enon (n = 1), Uhtoff’s phenomenon (n = 1), and segmental 
myoclonus (n = 1).
Investigations
Median haemoglobin level was 148 (range 117–170 g/L). 
All patients had normal mean cell volume (median 92.4; 
range 89.8–94.8 fL). Four patients had low vitamin  B12 lev-
els (median 191; range 109–2000 ng/L). MMA was meas-
ured in eight patients (median 2.9; range 0.16–110 μmol/L) 
and was not taken in patients whose  B12 level was below 
normal or elevated as a result of replacement. MMA was 
elevated in seven of the eight patients. Four of these could 
be deemed clinically relevant/revealing, with an associated 
normal  B12 level. Three were ‘complimentary’, with an asso-
ciated low  B12 level. The MMA level was normal in one 
patient whose vitamin  B12 level was low (case 7), but it tran-
spired that they had been aware of the risks of myelopathy 
and had been concurrently taking oral  B12 1000 μg once a 
day as prophylaxis. Despite this they had nonetheless devel-
oped subacute degeneration of the spinal cord.
A CSF examination was performed in four patients. 
White cell counts were < 1 in all cases. Protein was raised 
in two patients at 0.5 and 0.7 g/L (normal ≤ 0.4 g/L). Glu-
cose was within normal limits in all. Unmatched oligoclonal 
bands were demonstrated in one patient, the significance of 
which is unclear but would suggest a degree of intrathecal 
immunological response.
MRI of the spinal cord was performed in nine patients 
and showed  T2 signal change affecting the dorsal columns 
of the cervical spine, consistent with subacute degeneration 
of the spinal cord (see Fig. 1). In one patient, pathological 
enhancement was detected initially. Follow-up MRI was per-
formed in four patients after an average of 14 months (range 
5–27 months) from presentation. In two patients the signal 
change persisted and in the other two it had resolved. In the 
cases where MRI signal change had resolved (cases 7 and 
10), both received treatment for a minimum of 4 months. 
Case 7 had abstained from  N20, had been taking oral  B12 
prior to presenting, and was asymptomatic following treat-
ment. Case 10 continued to use  N20 once a fortnight and 
experienced persistent paraesthesia in the feet. The patient 
also had poor diabetic control, and nerve conduction stud-
ies demonstrated mixed axonal and demyelinating features 
consistent with diabetic neuropathy.
Management
All patients received hydroxocobalamin injections, 1 mg 
intramuscularly on alternate days, for a median of 2 weeks. 
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Four patients were lost to follow-up. Of the remaining six 
patients, two recovered without residual symptoms, three 
continued to have paraesthesia in the feet and one continued 
to have paraesthesia, gait ataxia, and proprioceptive sensory 
loss to the ankles (case 10 above).
Discussion
Recreational use of  N2O is largely through use of whipped 
cream chargers or ‘whippets’ bought from ‘head shops’ or 
online (see Fig. 2a). Whippets fit onto a dispenser, which is 
attached to a balloon that enables gas inhalation. Inhalation 
results in almost immediate psychotropic effects including 
euphoria, giggling, distortion of sound and mild hallucina-
tions, peaking after about 20 s before rapidly diminishing. 
Users often feel entirely normal within 2 min following 
inhalation. Side effects of dissociation, blurred vision, acute 
ataxia, nausea and headache have been reported [7].
Recreational use of  N2O in the UK has recently increased 
[7]. According to the Global Drug Survey, which collected 
data from over 100,000 drug users in 20 countries,  N2O is 
the seventh most popular recreational drug worldwide, and 
the fourth most commonly used by UK nightclub attendees, 
with 48% admitting to using the drug [1]. Since the Psycho-
active Substances Act came into effect in the UK in May 
2016, it has become illegal to supply  N2O for recreational 
consumption. Two recent high-profile cases of failed pros-
ecutions for  N2O supply have forced the Crown Prosecu-
tion Service to consider the implications for future cases 
[8]. Nonetheless, whippets are still being sold at a price of 
approximately £30 ($40) for 96 canisters.
Previous reports have been published of patients pre-
senting to hospital with acute pain and administration of 
Fig. 1  Pre- and post-treatment sagittal and axial T2 weighted MRI 
imaging of the cervical cord in  N2O-induced subacute degeneration 
of the spinal cord. a-1: Sagittal T2 weighted sequence demonstrat-
ing extensive cord signal change from the C2 to the C7 level within 
the dorsal aspect of the cord confirmed on the axial sequences, with 
enhancement (not shown). a-2: Taken 5  months following showing 
persistent abnormal T2 signal change within the dorsal columns on 
this sagittal T2 weighted sequence; however, the abnormal enhance-
ment had resolved (not shown). b-1: Sagittal T2 weighted sequence 
demonstrating cord signal change from C3 to C5 within the dor-
sal aspect of the cord confirmed on the axial sequences, without 
enhancement, and resolution over time (b-2)
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medicinal  N2O excessively, with subsequent development 
of subacute degeneration of the spinal cord [9]. However, 
routine use in anaesthesia or dental procedures only car-
ries a risk of subacute degeneration of the spinal cord in 
patients with low or low/normal serum vitamin  B12 [2, 6].
The deleterious effects of  N2O overuse are secondary to 
its interference with the action of vitamin  B12.  N2O causes 
oxidation of cobalt ions in vitamin  B12, leading to its inac-
tivation (see Fig. 2b). This results in reduced recycling 
of homocystine to methionine, preventing methylation of 
myelin proteins, thereby causing demyelination.
Identification of subacute degeneration of the spinal 
cord secondary to  N2O abuse requires a high index of sus-
picion and a thorough history, supported by the clinical 
examination, laboratory data and radiological findings. A 
normal vitamin  B12 level does not rule out the possibility 
of  N2O-induced subacute degeneration of the spinal cord, 
given that functional  B12 deficiency can occur in the pres-
ence of normal serum vitamin  B12 levels. In such cases, 
detecting raised MMA and homocystine, which rely on 
normally functioning vitamin  B12 for their metabolism, 
can give crucial clues to the diagnosis. Sagittal MRI imag-
ing demonstrates a classic appearance of T2 hyperinten-
sity in the dorsal spinal cord. Contrast enhancement is 
uncommon.
The management of patients includes educating them 
about the risks of  N2O and vitamin  B12 replacement using 
high-dose intramuscular hydroxocobalamin (1 mg on alter-
nate days until no further neurological improvement, fol-
lowed by 1 mg every 2 months) [10]. Neurological recovery 
may be incomplete, particularly when patients continue to 
use  N2O [6].
Our series revealed that  N2O-related subacute degen-
eration of the spinal cord tended to occur in young peo-
ple. While most were smokers, unexpectedly, and not in 
keeping with the habits of other drug users [11], the major-
ity did not drink alcohol or take other recreational drugs. 
However, this may also reflect the culture of the popula-
tion local to our hospital. The finding that 70% of patients 
were of Bangladeshi origin emphasises the importance of 
Fig. 2  a Discarded nitrous oxide canisters and balloons in East Lon-
don. b Metabolic pathway of vitamin  B12 involved in pathogenesis of 
 N2O-induced subacute degeneration of the spinal cord. Vitamin B12 
is a cofactor in the conversion of methylmalonyl-CoA to succinyl-
CoA and homocystine to methionine. Non-functioning  B12 leads to 
accumulation of methylmalonic acid and homocystine, which can be 
tested in the patient sera when  B12 levels appear normal, suggesting a 
‘functional;  B12 disorder. Figure created using Microsoft Word
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considering recreational drug use even when religious and/
or cultural assumptions may dissuade clinicians from this 
line of enquiry. The high Bangladeshi proportion also raises 
questions whether ethnicity-related metabolic, nutritional or 
genetic predispositions influence functional  B12 metabolism 
and predispose to neurological damage. Anecdotally, many 
 N2O users were not aware of the harmful effects of the drug 
and believed that because it was not previously illegal to 
consume, it was also safe to use.
The true scale of the problem is hard to gauge, but may 
only be improved through collaborative working by health 
professionals in neurology, public health and emergency 
medicine. Better recognition and accurate coding at the 
point of access to care will help ascertain the incidence and 
prevalence of neurological damage related to  N2O, and plan 
an effective public health response.
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